Summary
A loss?? Oh dear!!
Analysis
Don't cry or worry. They have Erbitux from ImClone as well as Alimta- Both blockbusters which will be lucrative for years. Alimta is now the base drug for 70% of lung cancer patients with well over 100K new patients/year. No problem!!
This author consults with leading institutions through GLG
Analyses are solely the work of the authors and have not been edited or endorsed by GLG.
